Pharmacy & Drug Policy
Expert articles and analysis related to pharmacy & drug policy.
AI Summary — Last 24 Hours
Synthesis:
In the past 24 hours, rapid developments in cell and gene therapy reimbursement have intensified scrutiny on cost-sharing mechanisms, with leading health policy voices arguing that current patient cost burdens primarily serve as financial rationing tools, potentially exacerbating health disparities rather than promoting value Healthcare Economist: cost sharing for cell & gene therapies. Simultaneously, momentum is building for substantive reforms to the 340B drug pricing program, as bipartisan policy discussions coalesce around lowering patient costs, promoting hospital transparency, and increasing taxpayer savings, all of which directly impact value-based payment models and ACO drug spending Healthcare Dive: 340B reforms. These trends signal growing pressure on CMS, Medicare Advantage plans, and provider organizations to recalibrate pharmacy benefit structures and align drug access policies with VBC incentives.
Related Articles
STAT+: The PBMs fight back, and arbitration doesn’t lose
We unpack the contentious fight over drug price transparency.
STAT+: PBMs warn Trump’s proposal to disclose drug prices is illegal
Pharma industry middlemen are pushing back on a major drug price transparency proposal.
AHA urges HRSA to abandon 340B rebate model that will cost billions and jeopardize access to care for millions
AHA urges HRSA to abandon 340B rebate model that will cost billions and jeopardize access to care for millions  American Hospital Association
AHA urges HRSA to axe 340B model that would cost hospitals $1B+ a year
AHA urges HRSA to axe 340B model that would cost hospitals $1B+ a year  Becker's Hospital Review
Federal 340B overhaul bill unlikely this year
A bipartisan Senate effort at 340B program reform is likely dead this Congress, according to lobbyists and policy watchers. The so-called gang of six group of senators has been working on an overhaul ...
An Arm and a Leg: The Accidental Architect of America’s Drug Patent Problem
An Arm and a Leg launches its “101” series with the story of Alfred Engelberg, a lawyer who’s been crusading to improve access to generic drugs by fixing loopholes in a law he helped draft more than 4...
10 pharmacy leaders on the revenue streams that’ll define survival by 2030
10 pharmacy leaders on the revenue streams that’ll define survival by 2030  Becker's Hospital Review
'Hospitals adverse to transparency'—clashing industry groups spar on mulligan 340B rebate pilot
'Hospitals adverse to transparency'—clashing industry groups spar on mulligan 340B rebate pilot  Fierce Healthcare
How Jefferson Health is coping with GLP-1 pressures in insurance coverage
How Jefferson Health is coping with GLP-1 pressures in insurance coverage  Becker's Hospital Review